As gene editing evolves from research to therapeutic applications, scientists seek unified platform approaches that help meet the rigorous demands of clinical precision, regulatory-compliancy, and manufacturing scalability. By integrating standardized, modular workflows, drug developers can reduce experimental variability and accelerate the path to clinical execution.
Validated guide RNA (gRNA) design and high-fidelity formats help scientists avoid off-target effects and current good manufacturing practice (cGMP) compliancy. AI-powered tools support efficient genotype-to-phenotype imaging analysis and automated toxicity and potency testing. Finally, technologies that scale from untargeted discovery to routine quantitation support manufacturing-ready analytics and data consolidation for investigational new drug (IND)-readiness.
The life sciences companies of Danaher provide a scalable Gene Editing Platform, offering standardized, modular building blocks throughout therapeutic development. IDT and Aldevron offer high-fidelity nucleases, sequence-verified guide RNAs, and scalable lipid nanoparticle (LNP) formulations that minimize off-target effects and maintain continuity from discovery to cGMP manufacturing.
Platform integration is designed to handle the complexity of modern editors. Beckman Coulter Life Sciences’ CytoFLEX nano Flow Cytometer enables nanoparticle analysis and the Optima AUC Analytical Ultracentrifuge provides gold standard LNP characterization for payload packaging efficiencies. The SCIEX ZenoTOF 8600 system delivers deep multiomics characterization within the same integrated platform, avoiding disruptive platform changes.
The CellXpress.ai® Automated Cell Culture System from Molecular Devices enables scalable expansion of edited 3D models. By automating organoid culture workflows, the system enables efficient, reliable toxicity and potency testing using physiologically relevant models. Post-editing functional assessment becomes fast and effortless with the ImageXpress® HCS.ai High Content Screening System and IN Carta® Image Analysis Software. Automated, multi-parametric toxicity and potency evaluation, powered by machine learning, streamlines analysis and improves data confidence.
For IND-ready data consolidation, the Genedata Biopharma Platform centralizes and connects next‑generation sequencing (NGS) and functional assay results, including chromatography, mass spectrometry, flow cytometry, and other assays, with full lineage and audit trails. It provides structured, annotated, traceable datasets and an integrated environment for AI-driven predictions, decisions and insights.
By adopting this integrated infrastructure, biopharmaceutical pioneers can improve drug candidate success rates, ensure process reliability at scale, and confidently navigate the path toward commercialization.
To learn more, sign up to receive the Designing CRISPR Genome Editing for Scale ebook.
